December 22, 2016
Janssen Pharmaceutical said on December 21 that it has filed a new drug application in Japan for its anti-CD38 monoclonal antibody daratumumab for the treatment of relapsed or refractory multiple myeloma (MM) both for use in monotherapy and combination therapy...read more